




U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2026-4269US1		SERIAL NO. 09/529,206			
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT WANG ET AL.					
		FILING DATE June 13, 2000		GROUP ART UNIT 1643			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
NAD		WO 94/03205	2/17/94	WIPO			
		WO 97/29195	8/4/97	WIPO			
		WO 98/14464	4/9/98	WIPO			
		WO 98 32855	6/30/98	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)							
NAD		Chen Y.-T., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94:1914 (1997).					
		Jager, E., et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187:265 (1998).					
		Parkhurst, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp 100 modified at HLA-A0201 binding residues. J. Immunol. 157:2539 (1996).					
		Wang, R., et al., A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different from different open reading frames. J. Immunol. 161:3596 (1998).					
		Falk et al. Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules Immunogenetics, Vol. 40: 238-241 (1994).					



FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2026-4269US1	SERIAL NO. 09/529,206
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT WANG ET AL.	
				FILING DATE June 13, 2000	
NAD		Kawakami, Y et al. Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating lymphocytes. J. Exp. Med., Vol. 180: 347 (1994).			
↓		Wang, R-F et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med., Vol. 181, 799-804 (1995).			
↓		Rammensee, H.G. et al. MHC ligand and peptide motifs: first listing, Immunogenetics, Vol. 41: 178 (1995).			
↓		Wang, R-F, et al. Utilization of an Alternative Open Reading Frame of a Normal Gene in Generating a Novel Human Cancer Antigen, J. Exp. Med. Vol. 183: 1131 (1996).			
↓		Wang and Rosenberg, Human tumor antigens recognized by T lymphocytes: implications for cancer therapy, J. Leukocyte Biology, Vol. 60: 296 (1996).			
↓		Wang, R-F et al., Identification of TRP-2 as a Human Tumor Antigen Recognized by cytotoxic T lymphocytes. J. Exp. Med., Vol. 184: 2203 (1996).			
↓		Kawakami Y et al. Identification of tumor-regression antigens in melanoma. 1. Important Advances in Oncology, 1996, eds. V. DeVita, S. Hellman, S.A. Rosenberg, Lippincott - Raven Publishers, Philadelphia, pp. 3-21			
EXAMINER		NAD		DATE CONSIDERED 9-15-01	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

M&F REV. 06/29/95